Dysbiosis and colorectal cancer: conducive factors, biological and molecular role, and therapeutic prospectives

Gurkaranjot Singh , Zuhair Chaudhry , Anik Boyadzhyan , Kayvan Sasaninia , Vikrant Rai

Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) : 1002329

PDF (3469KB)
Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) :1002329 DOI: 10.37349/etat.2025.1002329
Review
research-article
Dysbiosis and colorectal cancer: conducive factors, biological and molecular role, and therapeutic prospectives
Author information +
History +
PDF (3469KB)

Abstract

Colorectal cancer (CRC) is the third leading cause of cancer-related death in the United States. Emerging evidence highlights the significant role of gut microbiota dysbiosis, characterized by a reduction in beneficial bacteria and an increase in pro-inflammatory and pro-carcinogenic bacteria, in CRC pathogenesis. Both genetic and environmental factors, including diet, antibiotic use, physical activity, aging, and obesity, contribute to this microbial imbalance. Dysbiosis promotes chronic inflammation and immune dysregulation, which facilitates tumor initiation and progression. This review examines the intricate interactions between gut microbiota, immune modulation, and CRC development. It explores current and emerging therapeutic strategies that target the microbiome to enhance treatment efficacy, discusses interventions aimed at restoring healthy microbiota in CRC patients, and outlines future directions for microbiome-based therapies to improve clinical outcomes.

Keywords

Colorectal cancer / intestinal microbiome / inflammation / dysbiosis / immunomodulation / therapeutics

Cite this article

Download citation ▾
Gurkaranjot Singh, Zuhair Chaudhry, Anik Boyadzhyan, Kayvan Sasaninia, Vikrant Rai. Dysbiosis and colorectal cancer: conducive factors, biological and molecular role, and therapeutic prospectives. Exploration of Targeted Anti-tumor Therapy, 2025, 6 (1) : 1002329 DOI:10.37349/etat.2025.1002329

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023; 73: 233-54.

[2]

Ionescu VA, Gheorghe G, Bacalbasa N, Chiotoroiu AL, Diaconu C. Colorectal Cancer: From Risk Factors to Oncogenesis. Medicina (Kaunas). 2023; 59: 1646.

[3]

Abualkhair WH, Zhou M, Ahnen D, Yu Q, Wu X, Karlitz JJ. Trends in Incidence of Early-Onset Colorectal Cancer in the United States Among Those Approaching Screening Age. JAMA Netw Open. 2020; 3: e1920407. Erratum in: JAMA Netw Open. 2020; 3:e201038.

[4]

Han CJ, Yang GS, Syrjala K. Symptom Experiences in Colorectal Cancer Survivors After Cancer Treatments: A Systematic Review and Meta-analysis. Cancer Nurs. 2020; 43: E132-58.

[5]

Shin AE, Giancotti FG, Rustgi AK. Metastatic colorectal cancer: mechanisms and emerging therapeutics. Trends Pharmacol Sci. 2023; 44: 222-36.

[6]

Hossain MS, Karuniawati H, Jairoun AA, Urbi Z, Ooi DJ, John A, et al. Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies. Cancers (Basel). 2022; 14: 1732.

[7]

Sawicki T, Ruszkowska M, Danielewicz A, Niedźwiedzka E, Arłukowicz T, Przybyłowicz KE. A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis. Cancers (Basel). 2021; 13: 2025.

[8]

Fritz CDL, Otegbeye EE, Zong X, Demb J, Nickel KB, Olsen MA, et al. Red-flag signs and symptoms for earlier diagnosis of early-onset colorectal cancer. J Natl Cancer Inst. 2023; 115: 909-16.

[9]

Harada S, Morlote D. Molecular Pathology of Colorectal Cancer. Adv Anat Pathol. 2020; 27: 20-6.

[10]

Ladabaum U, Dominitz JA, Kahi C, Schoen RE. Strategies for Colorectal Cancer Screening. Gastroenterology. 2020; 158: 418-32.

[11]

Han C, Wu F, Xu J. Effectiveness of sigmoidoscopy or colonoscopy screening on colorectal cancer incidence and mortality: a systematic review and meta-analysis of randomized controlled trial. Front Oncol. 2024; 14: 1364923.

[12]

Chan DKH, Buczacki SJA. Tumour heterogeneity and evolutionary dynamics in colorectal cancer. Oncogenesis. 2021; 10: 53.

[13]

Liu Y, Chen H, Bao H, Zhang J, Wu R, Zhu L. Comprehensive characterization of FBXW7 mutational and clinicopathological profiles in human colorectal cancers. Front Oncol. 2023; 13: 1154432.

[14]

Wei W, Qin B, Wen W, Zhang B, Luo H, Wang Y, et al. FBXW7β loss-of-function enhances FASN-mediated lipogenesis and promotes colorectal cancer growth. Signal Transduct Target Ther. 2023; 8: 187.

[15]

Li B, Mi J, Yuan Q. Fatty acid metabolism-related enzymes in colorectal cancer metastasis: from biological function to molecular mechanism. Cell Death Discov. 2024; 10: 350.

[16]

Quaglio AEV, Grillo TG, De Oliveira ECS, Di Stasi LC, Sassaki LY. Gut microbiota, inflammatory bowel disease and colorectal cancer. World J Gastroenterol. 2022; 28: 4053-60.

[17]

Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, et al. What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. Microorganisms. 2019; 7: 14.

[18]

Kim CH. Complex regulatory effects of gut microbial short-chain fatty acids on immune tolerance and autoimmunity. Cell Mol Immunol. 2023; 20: 341-50.

[19]

Hrncir T. Gut Microbiota Dysbiosis: Triggers, Consequences, Diagnostic and Therapeutic Options. Microorganisms. 2022; 10: 578.

[20]

DeGruttola AK, Low D, Mizoguchi A, Mizoguchi E. Current Understanding of Dysbiosis in Disease in Human and Animal Models. Inflamm Bowel Dis. 2016; 22: 1137-50.

[21]

Adak A, Khan MR. An insight into gut microbiota and its functionalities. Cell Mol Life Sci. 2019; 76: 473-93.

[22]

Johansson MEV, Phillipson M, Petersson J, Velcich A, Holm L, Hansson GC. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci U S A. 2008; 105: 15064-9.

[23]

Xu J, Bjursell MK, Himrod J, Deng S, Carmichael LK, Chiang HC, et al. A genomic view of the human-Bacteroides thetaiotaomicron symbiosis. Science. 2003; 299: 2074-6.

[24]

Ruas-Madiedo P, Gueimonde M, Fernández-García M, de los Reyes-Gavilán CG, Margolles A. Mucin degradation by Bifidobacterium strains isolated from the human intestinal microbiota. Appl Environ Microbiol. 2008; 74: 1936-40.

[25]

Png CW, Lindén SK, Gilshenan KS, Zoetendal EG, McSweeney CS, Sly LI, et al. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol. 2010; 105: 2420-8.

[26]

Celli JP, Turner BS, Afdhal NH, Keates S, Ghiran I, Kelly CP, et al. Helicobacter pylori moves through mucus by reducing mucin viscoelasticity. Proc Natl Acad Sci U S A. 2009; 106: 14321-6.

[27]

Navarro-Garcia F, Gutierrez-Jimenez J, Garcia-Tovar C, Castro LA, Salazar-Gonzalez H, Cordova V. Pic, an autotransporter protein secreted by different pathogens in the Enterobacteriaceae family, is a potent mucus secretagogue. Infect Immun. 2010; 78: 4101-9.

[28]

Putsep K, Axelsson LG, Boman A, Midtvedt T, Normark S, Boman HG, et al. Germ-free and colonized mice generate the same products from enteric prodefensins. J Biol Chem. 2000; 275: 40478-82.

[29]

Wilson CL, Ouellette AJ, Satchell DP, Ayabe T, López-Boado YS, Stratman JL, et al. Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science. 1999; 286: 113-7.

[30]

Boneca IG, Dussurget O, Cabanes D, Nahori M, Sousa S, Lecuit M, et al. A critical role for peptidoglycan N-deacetylation in Listeria evasion from the host innate immune system. Proc Natl Acad Sci U S A. 2007; 104: 997-1002.

[31]

Iimura M, Gallo RL, Hase K, Miyamoto Y, Eckmann L, Kagnoff MF. Cathelicidin mediates innate intestinal defense against colonization with epithelial adherent bacterial pathogens. J Immunol. 2005; 174: 4901-7.

[32]

Cash HL, Whitham CV, Behrendt CL, Hooper LV. Symbiotic bacteria direct expression of an intestinal bactericidal lectin. Science. 2006; 313: 1126-30.

[33]

Bonamy C, Sechet E, Amiot A, Alam A, Mourez M, Fraisse L, et al. Expression of the human antimicrobial peptide β-defensin-1 is repressed by the EGFR-ERK-MYC axis in colonic epithelial cells. Sci Rep. 2018; 8: 18043.

[34]

Zhao X, Lu M, Liu Z, Zhang M, Yuan H, Dan Z, et al. Comprehensive analysis of alfa defensin expression and prognosis in human colorectal cancer. Front Oncol. 2023; 12: 974654.

[35]

Porter RJ, Murray GI, Alnabulsi A, Humphries MP, James JA, Salto-Tellez M, et al. Colonic epithelial cathelicidin (LL-37) expression intensity is associated with progression of colorectal cancer and presence of CD8+ T cell infiltrate. J Pathol Clin Res. 2021; 7: 495-506.

[36]

Macpherson AJ, Uhr T. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science. 2004; 303: 1662-5.

[37]

Rescigno M, Urbano M, Valzasina B, Francolini M, Rotta G, Bonasio R, et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol. 2001; 2: 361-7.

[38]

Suzuki K, Meek B, Doi Y, Muramatsu M, Chiba T, Honjo T, et al. Aberrant expansion of segmented filamentous bacteria in IgA-deficient gut. Proc Natl Acad Sci U S A. 2004; 101: 1981-6.

[39]

Kau AL, Planer JD, Liu J, Rao S, Yatsunenko T, Trehan I, et al. Functional characterization of IgA-targeted bacterial taxa from undernourished Malawian children that produce diet-dependent enteropathy. Sci Transl Med. 2015; 7: 276ra24.

[40]

Muthuswamy RV, Sundström P, Börjesson L, Gustavsson B, Quiding-Järbrink M. Impaired migration of IgA-secreting cells to colon adenocarcinomas. Cancer Immunol Immunother. 2013; 62: 989-97.

[41]

Nagaishi T, Watabe T, Kotake K, Kumazawa T, Aida T, Tanaka K, et al. Immunoglobulin A-specific deficiency induces spontaneous inflammation specifically in the ileum. Gut. 2022; 71: 487-96.

[42]

Tang Y, Feng X, Lu Q, Cui C, Yu M, Wen Z, et al. MZB1-mediated IgA secretion suppresses the development and progression of colorectal cancer triggered by gut inflammation. Mucosal Immunol. 2024; 17: 450-60.

[43]

Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006; 124: 783-801.

[44]

Chamaillard M, Hashimoto M, Horie Y, Masumoto J, Qiu S, Saab L, et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol. 2003; 4: 702-7.

[45]

Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nuñez G, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 2005; 307: 731-4.

[46]

Hooper LV, Midtvedt T, Gordon JI. How host-microbial interactions shape the nutrient environment of the mammalian intestine. Annu Rev Nutr. 2002; 22: 283-307.

[47]

Ivanov II, de Llanos Frutos Rosa, Manel N, Yoshinaga K, Rifkin DB, Sartor RB, et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe. 2008; 4: 337-49.

[48]

Fukata M, Shang L, Santaolalla R, Sotolongo J, Pastorini C, España C, et al. Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis. Inflamm Bowel Dis. 2011; 17: 1464-73.

[49]

Fukata M, Hernandez Y, Conduah D, Cohen J, Chen A, Breglio K, et al. Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors. Inflamm Bowel Dis. 2009; 15: 997-1006.

[50]

Pastille E, Faßnacht T, Adamczyk A, Phuong NNT, Buer J, Westendorf AM. Inhibition of TLR4 Signaling Impedes Tumor Growth in Colitis-Associated Colon Cancer. Front Immunol. 2021; 12: 669747.

[51]

Luo Q, Zeng L, Tang C, Zhang Z, Chen Y, Zeng C. TLR9 induces colitis-associated colorectal carcinogenesis by regulating NF-κB expression levels. Oncol Lett. 2020; 20: 110.

[52]

Sameer AS, Nissar S. Toll-Like Receptors (TLRs): Structure, Functions, Signaling, and Role of Their Polymorphisms in Colorectal Cancer Susceptibility. Biomed Res Int. 2021; 2021: 1157023.

[53]

Udden SMN, Peng L, Gan J, Shelton JM, Malter JS, Hooper LV, et al. NOD2 Suppresses Colorectal Tumorigenesis via Downregulation of the TLR Pathways. Cell Rep. 2017; 19: 2756-70.

[54]

Tralongo P, Tomasello G, Sinagra E, Damiani P, Leone A, Palumbo VD, et al. The role of butyric acid as a protective agent against inflammatory bowel diseases. Euromediterr Biomed J. 2014; 9: 24-35.

[55]

Parekh PJ, Balart LA, Johnson DA. The Influence of the Gut Microbiome on Obesity, Metabolic Syndrome and Gastrointestinal Disease. Clin Transl Gastroenterol. 2015; 6: e91.

[56]

Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012; 489: 220-30.

[57]

Wen L, Duffy A. Factors Influencing the Gut Microbiota, Inflammation, and Type 2 Diabetes. J Nutr. 2017; 147: 1468S-75S.

[58]

Yang J, Wu J, Li Y, Zhang Y, Cho WC, Ju X, et al. Gut bacteria formation and influencing factors. FEMS Microbiol Ecol. 2021; 97: fiab043.

[59]

Matute SP, Iyavoo S. Exploring the gut microbiota: lifestyle choices, disease associations, and personal genomics. Front Nutr. 2023; 10: 1225120.

[60]

Tomasello G, Abruzzo A, Sinagra E, Damiani P, Damiani F, Traina G, et al. Nutrition in IBD patient’s: what are the prospects? Prog Nutr. 2015; 17: 79-86.

[61]

Putignani L, Del Chierico F, Petrucca A, Vernocchi P, Dallapiccola B. The human gut microbiota: a dynamic interplay with the host from birth to senescence settled during childhood. Pediatr Res. 2014; 76: 2-10.

[62]

Hou K, Wu Z, Chen X, Wang J, Zhang D, Xiao C, et al. Microbiota in health and diseases. Signal Transduct Target Ther. 2022; 7: 135.

[63]

Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012; 22: 292-8.

[64]

Wang N, Fang J. Fusobacterium nucleatum, a key pathogenic factor and microbial biomarker for colorectal cancer. Trends Microbiol. 2023; 31: 159-72.

[65]

Tomasello G, Tralongo P, Damiani P, Sinagra E, Di Trapani B, Zeenny MN, et al. Dismicrobism in inflammatory bowel disease and colorectal cancer: changes in response of colocytes. World J Gastroenterol. 2014; 20: 18121-30.

[66]

Sinagra E, Tomasello G, Raimondo D, Rossi F, Facella T, Cappello F, et al. Nutrition, malnutrition and dietary interventions in inflammatory bowel disease. Prog Nutr. 2014; 16: 79-89.

[67]

de Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016; 13: 13-27.

[68]

Bellavia M, Tomasello G, Romeo M, Damiani P, Monte AIL, Lozio L, et al. Gut microbiota imbalance and chaperoning system malfunction are central to ulcerative colitis pathogenesis and can be counteracted with specifically designed probiotics: a working hypothesis. Med Microbiol Immunol. 2013; 202: 393-406.

[69]

Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015; 12: 205-17.

[70]

Venegas DP, De la Fuente MK, Landskron G, González MJ, Quera R, Dijkstra G, et al. Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. Front Immunol. 2019; 10: 277.

[71]

Weiss GA, Hennet T. Mechanisms and consequences of intestinal dysbiosis. Cell Mol Life Sci. 2017; 74: 2959-77.

[72]

Anand N, Gorantla VR, Chidambaram SB. The Role of Gut Dysbiosis in the Pathophysiology of Neuropsychiatric Disorders. Cells. 2022; 12: 54.

[73]

Zhao M, Chu J, Feng S, Guo C, Xue B, He K, et al. Immunological mechanisms of inflammatory diseases caused by gut microbiota dysbiosis: A review. Biomed Pharmacother. 2023; 164: 114985.

[74]

Wilmes P, Martin-Gallausiaux C, Ostaszewski M, Aho VTE, Novikova PV, Laczny CC, et al. The gut microbiome molecular complex in human health and disease. Cell Host Microbe. 2022; 30: 1201-6.

[75]

Olovo CV, Huang X, Zheng X, Xu M. Faecal microbial biomarkers in early diagnosis of colorectal cancer. J Cell Mol Med. 2021; 25: 10783-97.

[76]

Zhang W, An Y, Qin X, Wu X, Wang X, Hou H, et al. Gut Microbiota-Derived Metabolites in Colorectal Cancer: The Bad and the Challenges. Front Oncol. 2021; 11: 739648.

[77]

Silva M, Brunner V, Tschurtschenthaler M. Microbiota and Colorectal Cancer: From Gut to Bedside. Front Pharmacol. 2021; 12: 760280.

[78]

Pandey H, Tang DWT, Wong SH, Lal D. Gut Microbiota in Colorectal Cancer: Biological Role and Therapeutic Opportunities. Cancers (Basel). 2023; 15: 866.

[79]

Tilg H, Adolph TE, Gerner RR, Moschen AR. The Intestinal Microbiota in Colorectal Cancer. Cancer Cell. 2018; 33: 954-64.

[80]

Liu K, Yang X, Zeng M, Yuan Y, Sun J, He P, et al. The Role of Fecal Fusobacterium nucleatum and pks + Escherichia coli as Early Diagnostic Markers of Colorectal Cancer. Dis Markers. 2021; 2021: 1171239.

[81]

Zepeda-Rivera M, Minot SS, Bouzek H, Wu H, Blanco-Míguez A, Manghi P, et al. A distinct Fusobacterium nucleatum clade dominates the colorectal cancer niche. Nature. 2024; 628: 424-32.

[82]

Jin M, Shang F, Wu J, Fan Q, Chen C, Fan J, et al. Tumor-Associated Microbiota in Proximal and Distal Colorectal Cancer and Their Relationships With Clinical Outcomes. Front Microbiol. 2021; 12: 727937.

[83]

Nouri R, Hasani A, Shirazi KM, Alivand MR, Sepehri B, Sotoudeh S, et al. Mucosa-Associated Escherichia coli in Colorectal Cancer Patients and Control Subjects: Variations in the Prevalence and Attributing Features. Can J Infect Dis Med Microbiol. 2021; 2021: 2131787.

[84]

Becker HEF, Jamin C, Bervoets L, Boleij A, Xu P, Pierik MJ, et al. Higher Prevalence of Bacteroides fragilis in Crohn’s Disease Exacerbations and Strain-Dependent Increase of Epithelial Resistance. Front Microbiol. 2021; 12: 598232.

[85]

Oehmcke-Hecht S, Mandl V, Naatz LT, Dühring L, Köhler J, Kreikemeyer B, et al. Streptococcus gallolyticus abrogates anti-carcinogenic properties of tannic acid on low-passage colorectal carcinomas. Sci Rep. 2020; 10: 4714.

[86]

Haghi F, Goli E, Mirzaei B, Zeighami H. The association between fecal enterotoxigenic B. fragilis with colorectal cancer. BMC Cancer. 2019; 19: 879.

[87]

Appunni S, Rubens M, Ramamoorthy V, Tonse R, Saxena A, McGranaghan P, et al. Emerging Evidence on the Effects of Dietary Factors on the Gut Microbiome in Colorectal Cancer. Front Nutr. 2021; 8: 718389.

[88]

Chen F, Dai X, Zhou C, Li K, Zhang Y, Lou X, et al. Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma. Gut. 2022; 71: 1315-25.

[89]

Kong C, Liang L, Liu G, Du L, Yang Y, Liu J, et al. Integrated metagenomic and metabolomic analysis reveals distinct gut-microbiome-derived phenotypes in early-onset colorectal cancer. Gut. 2023; 72: 1129-42.

[90]

Guo X, Wang R, Chen R, Zhang Z, Wang J, Liu X. Gut microbiota and serum metabolite signatures along the colorectal adenoma-carcinoma sequence: Implications for early detection and intervention. Clin Chim Acta. 2024; 560: 119732.

[91]

Guzior DV, Quinn RA. Review: microbial transformations of human bile acids. Microbiome. 2021; 9: 140.

[92]

Larabi AB, Masson HLP, Bäumler AJ. Bile acids as modulators of gut microbiota composition and function. Gut Microbes. 2023; 15: 2172671.

[93]

Cong J, Liu P, Han Z, Ying W, Li C, Yang Y, et al. Bile acids modified by the intestinal microbiota promote colorectal cancer growth by suppressing CD8+ T cell effector functions. Immunity. 2024; 57: 876-89.e11.

[94]

Cao H, Xu M, Dong W, Deng B, Wang S, Zhang Y, et al. Secondary bile acid-induced dysbiosis promotes intestinal carcinogenesis. Int J Cancer. 2017; 140: 2545-56.

[95]

Litvak Y, Byndloss MX, Bäumler AJ. Colonocyte metabolism shapes the gut microbiota. Science. 2018; 362: eaat9076.

[96]

Ohara T, Mori T. Antiproliferative Effects of Short-chain Fatty Acids on Human Colorectal Cancer Cells via Gene Expression Inhibition. Anticancer Res. 2019; 39: 4659-66.

[97]

Mowat C, Dhatt J, Bhatti I, Hamie A, Baker K. Short chain fatty acids prime colorectal cancer cells to activate antitumor immunity. Front Immunol. 2023; 14: 1190810.

[98]

Zhang Q, Zhao Q, Li T, Lu L, Wang F, Zhang H, et al. Lactobacillus plantarum-derived indole-3-lactic acid ameliorates colorectal tumorigenesis via epigenetic regulation of CD8+ T cell immunity. Cell Metab. 2023; 35: 943-60.e9.

[99]

Zheng D, Dong X, Pan P, Chen K, Fan J, Cheng S, et al. Phage-guided modulation of the gut microbiota of mouse models of colorectal cancer augments their responses to chemotherapy. Nat Biomed Eng. 2019; 3: 717-28.

[100]

Teng H, Wang Y, Sui X, Fan J, Li S, Lei X, et al. Gut microbiota-mediated nucleotide synthesis attenuates the response to neoadjuvant chemoradiotherapy in rectal cancer. Cancer Cell. 2023; 41: 124-38.e6.

[101]

Xiao H, Cui M, Li Y, Dong J, Zhang S, Zhu C, et al. Gut microbiota-derived indole 3-propionic acid protects against radiation toxicity via retaining acyl-CoA-binding protein. Microbiome. 2020; 8: 69.

[102]

Tian T, Zhao Y, Yang Y, Wang T, Jin S, Guo J, et al. The protective role of short-chain fatty acids acting as signal molecules in chemotherapy- or radiation-induced intestinal inflammation. Am J Cancer Res. 2020; 10: 3508-31.

[103]

Wang Z, Wang Q, Wang X, Zhu L, Chen J, Zhang B, et al. Gut microbial dysbiosis is associated with development and progression of radiation enteritis during pelvic radiotherapy. J Cell Mol Med. 2019; 23: 3747-56.

[104]

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018; 359: 91-7.

[105]

Jiang S, Xie Y, Xiao X, Kang Z, Lin X, Zhang L, et al. Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. Cell Host Microbe. 2023; 31: 781-97.e9.

[106]

Zhang S, Mao Y, Zhang Z, Li Z, Kong C, Chen H, et al. Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer. Theranostics. 2021; 11: 4155-70.

[107]

Fong W, Li Q, Ji F, Liang W, Lau HCH, Kang X, et al. Lactobacillus gallinarum-derived metabolites boost anti-PD1 efficacy in colorectal cancer by inhibiting regulatory T cells through modulating IDO1/Kyn/AHR axis. Gut. 2023; 72: 2272-85.

[108]

Chen Z, Guan D, Wang Z, Li X, Dong S, Huang J, et al. Microbiota in cancer: molecular mechanisms and therapeutic interventions. MedComm (2020). 2023; 4: e417.

[109]

Yu T, Guo F, Yu Y, Sun T, Ma D, Han J, et al. Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy. Cell. 2017; 170: 548-63.e16.

[110]

Zhao L, Mei J, Yu G, Lei L, Zhang W, Liu K, et al. Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications. Signal Transduct Target Ther. 2023; 8: 201.

[111]

Duan B, Zhao Y, Bai J, Wang J, Duan X, Luo X, et al. Colorectal Cancer: An Overview. In: Morgado-Diaz JA, editor. Gastrointestinal Cancers. Brisbane (AU): Exon Publications; 2022. pp. 1-12.

[112]

Jafari MD, Carmichael JC, Dayyani F, McKinney C, Wenzel L, Zell JA, et al. Immediate Adjuvant Chemotherapy in Non-Metastatic Colon Cancer: Phase I Trial Evaluating a Novel Treatment Protocol. Clin Colorectal Cancer. 2022; 21: 114-21.

[113]

Wang J, Li S, Liu Y, Zhang C, Li H, Lai B. Metastatic patterns and survival outcomes in patients with stage IV colon cancer: A population-based analysis. Cancer Med. 2020; 9: 361-73.

[114]

Chen Y, Wang X, Ye Y, Ren Q. Gut microbiota in cancer: insights on microbial metabolites and therapeutic strategies. Med Oncol. 2023; 41: 25.

[115]

Chen Y, Liao X, Li Y, Cao H, Zhang F, Fei B, et al. Effects of prebiotic supplement on gut microbiota, drug bioavailability, and adverse effects in patients with colorectal cancer at different primary tumor locations receiving chemotherapy: study protocol for a randomized clinical trial. Trials. 2023; 24: 268.

[116]

Franko J, Raman S, Patel S, Petree B, Lin M, Tee MC, et al. Survival and cancer recurrence after short-course perioperative probiotics in a randomized trial. Clin Nutr ESPEN. 2024; 60: 59-64.

[117]

Xu F, Li Q, Wang S, Dong M, Xiao G, Bai J, et al. The efficacy of prevention for colon cancer based on the microbiota therapy and the antitumor mechanisms with intervention of dietary Lactobacillus. Microbiol Spectr. 2023; 11:e0018923.

[118]

Mego M, Chovanec J, Vochyanova-Andrezalova I, Konkolovsky P, Mikulova M, Reckova M, et al. Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study. Complement Ther Med. 2015; 23: 356-62.

[119]

Polakowski CB, Kato M, Preti VB, Schieferdecker MEM, Campos ACL. Impact of the preoperative use of synbiotics in colorectal cancer patients: A prospective, randomized, double-blind, placebo-controlled study. Nutrition. 2019; 58: 40-6.

[120]

Kvakova M, Kamlarova A, Stofilova J, Benetinova V, Bertkova I. Probiotics and postbiotics in colorectal cancer: Prevention and complementary therapy. World J Gastroenterol. 2022; 28: 3370-82.

[121]

Shao S, Jia R, Zhao L, Zhang Y, Guan Y, Wen H, et al. Xiao-Chai-Hu-Tang ameliorates tumor growth in cancer comorbid depressive symptoms via modulating gut microbiota-mediated TLR4/MyD88/NF-κB signaling pathway. Phytomedicine. 2021; 88: 153606.

[122]

Yu H, Li X, Han X, Chen B, Zhang X, Gao S, et al. Fecal microbiota transplantation inhibits colorectal cancer progression: Reversing intestinal microbial dysbiosis to enhance anti-cancer immune responses. Front Microbiol. 2023; 14: 1126808.

[123]

Van Dingenen L, Segers C, Wouters S, Mysara M, Leys N, Kumar-Singh S, et al. Dissecting the role of the gut microbiome and fecal microbiota transplantation in radio- and immunotherapy treatment of colorectal cancer. Front Cell Infect Microbiol. 2023; 13: 1298264.

[124]

Song M, Chan AT, Sun J. Influence of the Gut Microbiome, Diet, and Environment on Risk of Colorectal Cancer. Gastroenterology. 2020; 158: 322-40.

[125]

Rebersek M. Gut microbiome and its role in colorectal cancer. BMC Cancer. 2021; 21: 1325.

[126]

Yang J, Wei H, Zhou Y, Szeto C, Li C, Lin Y, et al. High-Fat Diet Promotes Colorectal Tumorigenesis Through Modulating Gut Microbiota and Metabolites. Gastroenterology. 2022; 162: 135-49.e2.

[127]

Molan A, Liu Z, Plimmer G. Evaluation of the effect of blackcurrant products on gut microbiota and on markers of risk for colon cancer in humans. Phytother Res. 2014; 28: 416-22.

[128]

Song M, Garrett WS, Chan AT. Nutrients, foods, and colorectal cancer prevention. Gastroenterology. 2015; 148: 1244-60.e16.

[129]

Aune D, Lau R, Chan DSM, Vieira R, Greenwood DC, Kampman E, et al. Dairy products and colorectal cancer risk: a systematic review and meta-analysis of cohort studies. Ann Oncol. 2012; 23: 37-45.

[130]

Kumar A, Chinnathambi S, Kumar M, Pandian GN. Food Intake and Colorectal Cancer. Nutr Cancer. 2023; 75: 1710-42.

[131]

Bullman S, Pedamallu CS, Sicinska E, Clancy TE, Zhang X, Cai D, et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science. 2017; 358: 1443-8.

[132]

Wang M, Rousseau B, Qiu K, Huang G, Zhang Y, Su H, et al. Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responses. Nat Biotechnol. 2024; 42: 1263-74.

PDF (3469KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉